Phosphagenics in for Indian royalties from TPM gels


By Dylan Bushell-Embling
Tuesday, 21 January, 2014

Phosphagenics (ASX:POH) has announced the launch of two anti-inflammatory products in India that use its targeted penetration matrix (TPM) drug-delivery technology.

Multinational pharmaceutical company Novartis has launched Voveran TPM Gel, a topical diclofenac gel formulated with the TPM system.

Phosphagenics’ Indian marketing partner, Themis Medicare, is also gearing up to launch its own diclofenac product incorporating TPM under the product name Instanac TPM Gel.

Themis Medicare took out a licence to use Phosphagenics’ TPM technology in a branded diclofenac product in late 2011. Last year, the company entered an agreement with Novartis to manufacture and supply the Voveran TPM Gel.

Under the terms of these deals, Phosphagenics is entitled to undisclosed royalties on sales of both branded products.

Voveran TPM gel will be marketed for the treatment of pain and inflammation of the muscles and joints caused by osteoarthritis, soft tissue rheumatism and injuries such as sprains and strains. The product packaging will highlight the use of the TPM delivery system.

Phosphagenics (ASX:POH) shares were trading unchanged at $0.13 as of around 2 pm on Tuesday.

Related News

Cancer drug eliminates bone metastasis in lab models

Researchers have developed a novel treatment that is specific to breast cancer bone metastasis...

TGA rejects Alzheimer's drug due to safety concerns

The TGA determined that the demonstrated efficacy of lecanemab in treating Alzheimer's did...

Defective sperm doubles pre-eclampsia risk in IVF patients

A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd